Navigation Links
Hebrew University researchers identify gene related to chronic pain

Jerusalem, August 4, 2010 Researchers at the Hebrew University of Jerusalem and elsewhere have succeeded in identifying for the first time a gene associated with susceptibility to chronic pain caused by nerve injury in humans, signaling a significant step toward better understanding and treating of the condition.

Chronic pain is a serious medical problem, afflicting approximately 20% of adults. Some individuals are more susceptible than others, and the degree of pain experienced after injury or surgery is known to be highly variable between patients, even under nearly identical circumstances.

The basis for this has remained largely unknown, prompting researchers to search for the contribution of genetics to chronic pain susceptibility. To accelerate research in this field, animal models are proving to be critical to understanding the underlying biology of chronic pain in human patients.

In a report to be published online on Aug. 5 in Genome Research (, Prof. Ariel Darvasi of the Alexander Silberman Institute of Life Sciences at the Hebrew University of Jerusalem and colleagues identified a region of mouse chromosome 15 that likely contained a genetic variant or variants contributing to pain. However, this region contains many genes, and the responsible variant remained unknown.

Darvasi and an international team of researchers that included Prof. Marshall Devor of the Hebrew University and Canadian and European scientists undertook two fine-mapping approaches to narrow down the chromosomal locus to an interval of 155 genes.

By applying bioinformatics approaches and whole genome microarray analysis, they then were able to confidently identify a single gene, Cacgn2, as the likely candidate.

To further test the potential role for Cacgn2 in chronic pain, the authors utilized a mouse strain harboring a mutant version of the gene that had previously been used in epilepsy research. In testing the mice for behavioral and electrophysiological characteristics of chronic pain, they found that, the observations were consistent with a functional role for Cacgn2 in pain, even though it might be modest.

However, the question still remained as to whether the human version of the gene also is important for chronic pain. Analyzing a cohort of breast cancer patients who experienced chronic pain half a year or more after they that had undergone removal or partial removal of a breast, they found that genetic variants of Cacng2 were significantly associated with this chronic pain. The authors cautioned that although this association will need to be analyzed further, the result is encouraging at pointing to this gene as a significant factor in experiencing pain.

"The immediate significance is the mere awareness that differences in pain perception may have a genetic predisposition," Darvasi explained. "Our discovery may provide insights for treating chronic pain through previously unthought-of mechanisms."


Contact: Jerry Barach
The Hebrew University of Jerusalem

Related biology news :

1. Research on stem cells wins first prize for Hebrew University researcher
2. JDRF, Pfizer, Hadassah Medical and the Hebrew University announce collaboration
3. Hebrew University, American researchers show trigger to stem cell differentiation
4. Regulatory role of key molecule discovered at Hebrew U.
5. Alert status area in brain discoved by Hebrew University scientists
6. Ben-Gurion U. developing new computer techniques to analyze historic Hebrew and Arabic documents
7. Hebrew U. researchers shed light on the brain mechanism responsible for processing of speech
8. Promising new treatment for Alzheimers suggested based on Hebrew University research
9. Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
10. Hebrew University professors work leads to FDA approval for product
11. Hebrew University scientists reveal mechanism that triggers differentiation of embryo cells
Post Your Comments:
Related Image:
Hebrew University researchers identify gene related to chronic pain
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
Breaking Biology Technology: